Dr. Wolchok is the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK); chief of the Melanoma and Immunotherapeutics Service at MSK; and an attending physician at MSK with an expertise in the treatment of metastatic melanoma. His additional appointments include: head of the Swim Across America/Ludwig Collaborative Laboratory; associate director of the Ludwig Center for Cancer Immunotherapy; and director of the Parker Institute for Cancer Immunotherapy at MSK. Dr. Wolchok has helped establish MSK as a leader in the discovery of novel immunotherapies to treat cancers. He was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma, and recently designed and led a global phase 3 trial of combined checkpoint blockade for melanoma. Dr. Wolchok has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials. In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies and has become a model for similar efforts by other major cancer centers throughout the world.
Jedd D.
Wolchok
Memorial Sloan Kettering Cancer Center
New York, NY